Combination cancer immunotherapy and new immunomodulatory targets

Nature Reviews Drug Discovery

Volumn 14, Issue 8, 2015, Pages 561-584

  Mahoney, Kathleen M ^a   Rennert, Paul D ^b,c   Freeman, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SugarCone Biotech   (United States)

^c Videre Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; B RAF KINASE INHIBITOR; B7 ANTIGEN; BEVACIZUMAB; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; DABRAFENIB; DACARBAZINE; DEATH RECEPTOR 3; DURVALUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PF 05082566; PROTEIN LAG3; RITUXIMAB; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SUNITINIB; TRAMETINIB; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; URELUMAB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY CANCER; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84938350452     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4591     Document Type: Review

References (270)

1. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565- 1570 (2011).
2. Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522-529 (2014).
3. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
4. Freeman, G. J. et al. Engagement of the PD 1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
5. Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
6. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
7. Powles, T. et al. MPDL3280A (anti PD L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
8. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti PD 1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
9. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death 1 (MDX 1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
10. Herbst, R. S. et al. Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
11. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
12. Le, D. T. et al. PD 1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. http://dx.doi. org/10.1056/nejmoa1500596 (2015).
13. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. http://dx.doi. org/10.1056/nejmoa1503093 (2015).
14. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. http://dx.doi.org/10.1056/nejmoa1504030 (2015).
15. Schadendorf, D. et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
16. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
17. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
18. Jenkins, M. K. & Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
19. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
20. Antonia, S. J. et al. Nivolumab (anti PD 1; BMS 936558, ONO 4538) and ipilimumab in first-line NSCLC: interim phase I results. J. Clin. Oncol. 32 Suppl., 8023 (2014).
21. Antonia, S. J. et al. Nivolumab (anti PD 1; BMS 936558, ONO 4538) in combination with platinum-based doublet chemotherapy (PT DC) in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32 Suppl., 8113 (2014).
22. Amin, A. et al. Nivolumab (anti PD 1; BMS 936558, ONO 4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32 Suppl., 5010 (2014).
23. Hammers, H. et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32 Suppl., 4504 (2014).
24. Hamid, O. S. et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 31 Suppl., 9010 (2013).
25. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
26. Antonia, S. et al. Phase Ib study of MEDI4736, a programmed cell death ligand 1 (PD L1) antibody, in combination with tremelimumab, a cytotoxic T lymphocyte-associated protein 4 (CTLA 4) antibody, in patients (pts) with advanced NSCLC. J. Clin. Oncol. 33 Suppl., 3014 (2015
27. Parry, R. V. et al. CTLA 4 and PD 1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543-9553 (2005).
28. Korman, A. et al. Activity of anti PD 1 in murine tumor models: role of "host" PD L1 and synergistic effect of anti PD 1 and anti-CTLA 4. J. Immunol. 178 Suppl., S82 (2007).
29. Freeman, G. J. & Sharpe, A. H. A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat. Immunol. 13, 113-115 (2012).
30. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
31. Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD L1 blockade. Cancer Res. 74, 5458-5468 (2014).
32. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD 1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
33. Postow, M. A. et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J. Clin. Oncol. 31 Suppl., 9052 (2013).
34. Le, D. T. & Jaffee, E. M. Regulatory T cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439-3444 (2012).
35. Vincent, J. et al. 5 Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
36. Sevko, A. et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464-2471 (2013).
37. Hannani, D. et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 17, 351-358 (2011).
38. Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774-11779 (2014).
39. Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mule, J. J. & Rosenberg, S. A. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 46, 5618-5623 (1986).
40. Mier, J. W. et al. Inhibition of interleukin 2 induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin 2 associated side effects. Blood 76, 1933-1940 (1990).
41. Vetto, J. T., Papa, M. Z., Lotze, M. T., Chang, A. E. & Rosenberg, S. A. Reduction of toxicity of interleukin 2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J. Clin. Oncol. 5, 496-503 (1987).
42. Wolchok, J. et al. Efficacy and safety results from a Phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol. 33 Suppl., LBA1 (2015).
43. Donia, M. et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T cell transfer. Oncoimmunology 1, 1476-1483 (2012).
44. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231 (2013).
45. Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J. & Hodi, F. S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res. 19, 598-609 (2013).
46. Cooper, Z. A. et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2, 643- 654 (2014).
47. Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
48. Ribas, A. et al. Phase I study combining anti PD L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 33 Suppl., 3003 (2015).
49. Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739-752 (2013).
50. Finke, J. et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856-861 (2011).
51. Bhatt, R. S. et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol. Cancer Ther. 9, 2793-2802 (2010).
52. Salven, P., Orpana, A., Teerenhovi, L. & Joensuu, H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non- Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96, 3712-3718 (2000).
53. Zhan, P., Qian, Q. & Yu, L. K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg. Nutr. 2, 209-215 (2013).
54. Yuan, J. et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2, 127-132 (2014).
55. Ohm, J. E. & Carbone, D. P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23, 263-272 (2001).
56. Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
57. Lieu, C. et al. Safety and efficacy of MPDL3280A (anti PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors. Ann. Oncol. 25 (Suppl. 4): iv361-iv372 (2014).
58. Ellis, L. M. The role of neuropilins in cancer. Mol. Cancer Ther. 5, 1099-1107 (2006).
59. Chaudhary, B., Khaled, Y. S., Ammori, B. J. & Elkord, E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol. Immunother. 63, 81-99 (2014).
60. Papatriantafyllou, M. T cells: neuropilin 1 - distinguishing TReg cell subsets. Nat. Rev. Immunol. 12, 746 (2012).
61. Grandclement, C. & Borg, C. Neuropilins: a new target for cancer therapy. Cancers (Basel) 3, 1899-1928 (2011).
62. Weekes, C. D. et al. A Phase I study of the human monoclonal anti NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest. New Drugs 32, 653-660 (2014).
63. Patnaik, A. et al. Phase Ib study evaluating MNRP1685A, a fully human anti NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 951-960 (2014).
64. Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin 1 semaphorin 4a axis. Nature 501, 252-256 (2013).
65. Vilcek, J. & Feldmann, M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 25, 201-209 (2004).
66. Schaer, D. A., Hirschhorn-Cymerman, D. & Wolchok, J. D. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J. Immunother. Cancer 2, 7 (2014).
67. Kwon, B. S. et al. Immune responses in 4 1BB (CD137)-deficient mice. J. Immunol. 168, 5483-5490 (2002).
68. Chester, C. et al. Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS 663513) in subjects with advanced solid tumors and relapsed/refractory B cell non-Hodgkin lymphoma. J. Clin. Oncol. 32 Suppl., 3017 (2014).
69. Hwu, W. Targeted therapy for metastatic melanoma: from bench to bedside. HemOnc Today [online], http://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/print/hemonc-today/%7B77e71a11- 1fd1-4193-a2f7-7c50c6121c1f%7D/targeted-therapy-for-metastatic-melanoma-from-bench-to-bedside (2010).
70. Segal, N. H. et al. A phase 1 study of PF 05082566 (anti 4 1BB) in patients with advanced cancer. J. Clin. Oncol. 32 Suppl., 3007 (2014).
71. Gopal, A. et al. A phase I study of PF 05082566 (anti 4 1BB) + rituximab in patients with CD20+ NHL. J. Clin. Oncol. 33 Suppl., 3004 (2015).
72. Kohrt, H. E. et al. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124, 2668-2682 (2014).
73. Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44-55 (2014).
74. Bulliard, Y. et al. OX40 engagement depletes intratumoral Tregs via activating Fc?Rs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475-480 (2014).
75. Guo, Z. et al. PD 1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9, e89350 (2014).
76. Guo, Z. et al. Combined TIM 3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J. Transl. Med. 11, 215 (2013).
77. Adler, A. J. & Vella, A. T. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co stimulation. Oncoimmunology 2, e22837 (2013).
78. Wei, H. et al. Combinatorial PD 1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE 8, e84927 (2013).
79. Kovacsovics-Bankowski, M. et al. Phase I/II clinical trial of anti OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. J. Immunother. Cancer 1, 255 (2013).
80. Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189-7198 (2013).
81. Cohen, A. D. et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5, e10436 (2010).
82. Lu, L. et al. Combined PD 1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
83. Grewal, I. S. CD70 as a therapeutic target in human malignancies. Expert Opin. Ther. Targets 12, 341-351 (2008).
84. Ansell, S. M. et al. Phase I evaluation of an agonist anti CD27 human antibody (CDX 1127) in patients with advanced hematologic malignancies. J. Clin. Oncol. 32 Suppl., 3034 (2014).
85. Infante, J. R. et al. Immunologic activity of an activating anti CD27 antibody (CDX 1127) in patients (pts) with solid tumors. J. Clin. Oncol. 32 Suppl., 3027 (2014).
86. Twohig, J. P. et al. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T cell immunity. FASEB J. 26, 3575-3586 (2012).
87. Bossen, C. et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281, 13964-13971 (2006).
88. Meylan, F. et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29, 79-89 (2008).
89. Slebioda, T. J. et al. Triggering of TNFRSF25 promotes CD8+ T cell responses and anti-tumor immunity. Eur. J. Immunol. 41, 2606-2611 (2011).
90. Schreiber, T. H. & Podack, E. R. Immunobiology of TNFSF15 and TNFRSF25. Immunol. Res. 57, 3-11 (2013).
91. Schreiber, T. H., Wolf, D., Bodero, M., Gonzalez, L. & Podack, E. R. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J. Immunol. 189, 3311-3318 (2012).
92. Bodmer, J. L., Schneider, P. & Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26 (2002
93. Bajor, D. et al. Combination of agonistic CD40 monoclonal antibody CP 870, 893 and anti-CTLA 4 antibody tremelimumab in patients with metastatic melanoma. American Association for Cancer Research Annual Meeting [online], http://www.abstractsonline. com/Plan/ViewAbstract.aspx?mID=3682& sKey= b6e2d928-3a12-44b7-9f8a-3a69ffde9741& cKey= b51efb80-7710-4f0e-949b-623213c6ff47& mKey =19573a54-ae8f-4e00-9c23-bd6d62268424 (2015).
94. Zippelius, A., Schreiner, J., Herzig, P. & Muller, P. Induced PD L1 expression mediates acquired resistance to agonistic anti CD40 treatment. Cancer Immunol. Res. 3, 236-244 (2015).
95. Medina-Echeverz, J. et al. Systemic agonistic anti CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol. Res. 3, 557-566 (2015).
96. Cai, G. et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 9, 176-185 (2008).
97. Derre, L. et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120, 157- 167 (2010).
98. Pasero, C. & Olive, D. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol. Lett. 151, 71-75 (2013).
99. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA 4 and PD 1. Nat. Immunol. 4, 670-679 (2003).
100. Huang, C. T. et al. Role of LAG 3 in regulatory T cells. Immunity 21, 503-513 (2004).
101. Woo, S. R. et al. Immune inhibitory molecules LAG 3 and PD 1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
102. Matsuzaki, J. et al. Tumor-infiltrating NY ESO 1 specific CD8+ T cells are negatively regulated by LAG 3 and PD 1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875-7880 (2010).
103. Wang-Gillam, A. et al. A Phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest. New Drugs 31, 707-713 (2013).
104. Brignone, C. et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG 3Ig) enhances immune responses and antitumor activity. J. Transl. Med. 8, 71 (2010).
105. Brignone, C., Escudier, B., Grygar, C., Marcu, M. & Triebel, F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15, 6225-6231 (2009).
106. McIntire, J. J. et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. 2, 1109-1116 (2001).
107. Freeman, G. J., Casasnovas, J. M., Umetsu, D. T. & DeKruyff, R. H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 235, 172-189 (2010).
108. Jin, H. T. et al. Cooperation of Tim 3 and PD 1 in CD8 T cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
109. Sakuishi, K. et al. Targeting Tim 3 and PD 1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
110. Zhu, C. et al. The Tim 3 ligand galectin 9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252 (2005).
111. Huang, Y. H. et al. CEACAM1 regulates TIM 3 mediated tolerance and exhaustion. Nature 517, 386-390 (2015).
112. DeKruyff, R. H. et al. T cell/transmembrane, Ig, and mucin 3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184, 1918-1930 (2010).
113. Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C. & Kuchroo, V. K. Emerging Tim 3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345-349 (2011).
114. Madireddi, S. et al. Galectin 9 controls the therapeutic activity of 4 1BB targeting antibodies. J. Exp. Med. 211, 1433-1448 (2014).
115. Gleason, M. K. et al. Tim 3 is an inducible human natural killer cell receptor that enhances interferon ? production in response to galectin 9. Blood 119, 3064-3072 (2012).
116. Pillai, S., Netravali, I. A., Cariappa, A. & Mattoo, H. Siglecs and immune regulation. Annu. Rev. Immunol. 30, 357-392 (2012).
117. Jandus, C. et al. Interactions between Siglec 7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810-1820 (2014).
118. Laubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl Acad. Sci. USA 111, 14211-14216 (2014).
119. Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N. & Angata, T. The interaction between Siglec 15 and tumor-associated sialyl Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12 Syk pathway. Glycobiology 23, 178-187 (2013).
120. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
121. Chen, L. & Flies, D. B. Molecular mechanisms of T cell co stimulation and co inhibition. Nat. Rev. Immunol. 13, 227-242 (2013).
122. Zhao, R. et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Proc. Natl Acad. Sci. USA 110, 9879-9884 (2013).
123. Sharpe, A. H. Mechanisms of costimulation. Immunol. Rev. 229, 5-11 (2009).
124. Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F. & Alesse, E. Targeting costimulatory molecules to improve antitumor immunity. J. Biomed. Biotechnol. 2012, 926321 (2012).
125. Ng Tang, D. et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti- CTLA 4 therapy. Cancer Immunol. Res. 1, 229-234 (2013).
126. Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P. & Allison, J. P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA 4 blockade in cancer immunotherapy. J. Exp. Med. 211, 715-725 (2014).
127. Yap, E. H., Rosche, T., Almo, S. & Fiser, A. Functional clustering of immunoglobulin superfamily proteins with protein-protein interaction information calibrated hidden Markov model sequence profiles. J. Mol. Biol. 426, 945-961 (2014).
128. Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933-1944 (2014).
129. Janakiram, M. et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 21, 2359-2366 (2015).
130. Zhu, Y. et al. B7 H5 costimulates human T cells via CD28H. Nat. Commun. 4, 2043 (2013).
131. Nguyen, T., Liu, X. K., Zhang, Y. & Dong, C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J. Immunol. 176, 7354-7360 (2006).
132. Valentonyte, R. et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat. Genet. 37, 357-364 (2005).
133. Arnett, H. A. & Viney, J. L. Immune modulation by butyrophilins. Nat. Rev. Immunol. 14, 559-569 (2014).
134. Fitzgerald, L. M. et al. Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 22, 1520-1528 (2013).
135. Vijai, J. et al. A genome-wide association study suggests evidence of variants at 6p21.32 associated with marginal zone lymphoma. Cancer Res. 74 (Suppl. 19), 5071 (2014).
136. Abeler-Dorner, L., Swamy, M., Williams, G., Hayday, A. C. & Bas, A. Butyrophilins: an emerging family of immune regulators. Trends Immunol. 33, 34-41 (2012).
137. Rubinstein, R., Ramagopal, U. A., Nathenson, S. G., Almo, S. C. & Fiser, A. Functional classification of immune regulatory proteins. Structure 21, 766-776 (2013).
138. de Andrade, L. F., Smyth, M. J. & Martinet, L. DNAM 1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol. Cell Biol. 92, 237-244 (2014).
139. Sema Kurtulus, S. et al. Mechanisms of TIGIT-driven immune suppression in cancer. J. Immunother. Cancer 2 (Suppl. 3), O13 (2014).
140. Chauvin, J. M. et al. TIGIT and PD 1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest. 125, 2046-2058 (2015).
141. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26, 923-937 (2014).
142. Guillerey, C. et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J. Clin. Invest. 125, 2077-2089 (2015).
143. Li, A. H. et al. Analysis of loss of function variants and 20 risk factor phenotypes in 8, 554 individuals identifies loci influencing chronic disease. Nat. Genet. 47, 640-642 (2015).
144. Beano, A. et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl. Med. 6, 25 (2008).
145. Vey, N. et al. A Phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317-4323 (2012).
146. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781-790 (2003).
147. Spear, P., Wu, M. R., Sentman, M. L. & Sentman, C. L. NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8 (2013).
148. Farnault, L., Sanchez, C., Baier, C., Le Treut, T. & Costello, R. T. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin. Dev. Immunol. 2012, 421702 (2012).
149. Bonnafous, C. et al. Targeting MICA with therapeutic antibodies for the treatment of cancer (Poster). J. Immunother. Cancer 1 (Suppl. 1), P41 (2013).
150. Wada, H., Matsumoto, N., Maenaka, K., Suzuki, K. & Yamamoto, K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA E through mostly shared but partly distinct sets of HLA E residues. Eur. J. Immunol. 34, 81-90 (2004).
151. Chretien, A. S. et al. Cancer-induced alterations of NK mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK mediated anti-tumor activity. Front. Immunol. 5, 122 (2014).
152. Sheu, J. & Shih, le-M. HLA G and immune evasion in cancer cells. J. Formos Med. Assoc. 109, 248-257 (2010).
153. Alegre, E. et al. Some basic aspects of HLA G biology. J. Immunol. Res. 2014, 657625 (2014).
154. González, A. et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit. Rev. Clin. Lab Sci. 49, 63-84 (2012).
155. Stark, S. & Watzl, C. 2B4 (CD244), NTB A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int. Immunol. 18, 241-247 (2006).
156. Valiante, N. M. & Trinchieri, G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178, 1397-1406 (1993).
157. Ljunggren, H. G. & Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329-339 (2007).
158. Munn, D. H. Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. (Elite Ed) 4, 734-745 (2012).
159. Gibney, G. T. et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J. Clin. Oncol. 32 Suppl., 3010 (2014).
160. Soliman, H. H. et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5, 8136-8146 (2014).
161. [No authors listed.] NewLink Genetics announces exclusive worldwide licensing agreement for development of NLG919, an IDO inhibitor in Phase 1, and research collaboration for the discovery of next generation IDO/TDO inhibitors. NewLink Genetics [online], http://investors.linkp.com/releasedetail. cfm?releaseid=876909 (2014).
162. [No authors listed.] Bristol-Myers Squibb to expand its immuno-oncology pipeline with agreement to acquire Flexus Biosciences, Inc. Bristol-Myers Squibb [online], http://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle (2015).
163. Margadant, C. & Sonnenberg, A. Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97-105 (2010).
164. Gueorguieva, I. et al. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br. J. Clin. Pharmacol. 77, 796-807 (2014).
165. Bhola, N. E. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348-1358 (2013).
166. Bedi, A. et al. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol. Cancer Ther. 11, 2429-2439 (2012).
167. Hanks, B. A., Holtzhausen, A., Evans, K., Heid, M. & Blobe, G. C. Combinatorial TGF β signaling blockade and anti-CTLA 4 antibody immunotherapy in a murine BRAFV600E PTEN-/- transgenic model of melanoma. J. Clin. Oncol. 32 Suppl., 3011 (2014).
168. Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410 (2011).
169. Ohta, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006).
170. Cekic, C. & Linden, J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res. 74, 7239-7249 (2014).
171. Jones, G. B. & Yuan, G. Towards next generation adenosine A2A receptor antagonists. Curr. Med. Chem. 21, 3918-3935 (2014).
172. Yegutkin, G. G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783, 673-694 (2008).
173. Mandapathil, M. et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 285, 7176-7186 (2010).
174. Iannone, R., Miele, L., Maiolino, P., Pinto, A. & Morello, S. Adenosine limits the therapeutic effectiveness of anti CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4, 172-181 (2014).
175. Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti PD 1 and anti-CTLA 4 mAbs. Clin. Cancer Res. 19, 5626-5635 (2013).
176. Hatfield, S. M. et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 7, 277ra30 (2015).
177. Cekic, C., Day, Y. J., Sag, D. & Linden, J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74, 7250-7259 (2014).
178. Morello, S. & Miele, L. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. OncoImmunology 3, e27989 (2014).
179. Hoskin, D. W., Mader, J. S., Furlong, S. J., Conrad, D. M. & Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 32, 527-535 (2008).
180. Srivastava, M. K. et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7, e40677 (2012).
181. Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti PD L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212-20217 (2013).
182. Luster, T. A. et al. Plasma protein β 2 glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J. Biol. Chem. 281, 29863-29871 (2006).
183. Shtivelband, M. et al. Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. J. Clin. Oncol. 31 Suppl., 8095 (2013).
184. Yopp, A. et al. Antibody-mediated blockade of phosphatidylserine enhances the antitumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment. J. Immunother. Cancer 2 (Suppl. 3), P266 (2014).
185. Huang, X. et al. Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma. J. Immunother. Cancer 2 (Suppl. 3), P205 (2014).
186. Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665-673 (2014).
187. Tseng, D. et al. Anti CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T cell response. Proc. Natl Acad. Sci. USA 110, 11103-11108 (2013).
188. Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88-91 (2013).
189. Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
190. Chao, M. P. et al. Anti CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
191. Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509-524 (2014).
192. Taube, J. M. et al. Colocalization of inflammatory response with B7 h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012).
193. Jass, J. R. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 39, 585-589 (1986).
194. Sobin, L
195. Mlecnik, B., Bindea, G., Pages, F. & Galon, J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 30, 5-12 (2011).
196. Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).
197. Angell, H. & Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261-267 (2013).
198. Messina, J. L. et al. 12 chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci. Rep. 2, 765 (2012).
199. Thompson, R. H. et al. Costimulatory B7 H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174-17179 (2004).
200. Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. http://dx.doi. org/10.1158/1078-0432.CCR-14-2926 (2015).
201. Tumeh, P. C. et al. PD 1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
202. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J.Med. 365, 725-733 (2011).
203. John, L. B. et al. Anti PD 1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646 (2013).
204. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
205. Nordlund, J. J. et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9, 689-696 (1983).
206. Bystryn, J. C., Rigel, D., Friedman, R. J. & Kopf, A. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123, 1053-1055 (1987).
207. Scalzo, S. et al. Primary hypothyroidism associated with interleukin 2 and interferon α 2 therapy of melanoma and renal carcinoma. Eur. J. Cancer 26, 1152-1156 (1990).
208. Becker, J. C., Winkler, B., Klingert, S. & Brocker, E. B. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73, 1621-1624 (1994).
209. Rosenberg, S. A. & White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81-84 (1996).
210. Atkins, M. B. et al. Hypothyroidism after treatment with interleukin 2 and lymphokine-activated killer cells. N. Engl. J. Med. 318, 1557-1563 (1988).
211. Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen 4. J. Clin. Oncol. 23, 6043-6053 (2005).
212. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
213. Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283-2289 (2006).
214. Kyi, C., Carvajal, R. D., Wolchok, J. D. & Postow, M. A. Ipilimumab in patients with melanoma and autoimmune disease. J. Immunother. Cancer 2, 35 (2014).
215. Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA 4 blockade. Cancer Res. 60, 2444-2448 (2000).
216. Hodi, F. S. et al. Ipilimumab plus sargramostim versus ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744-1753 (2014).
217. Jinushi, M. et al. MFG E8 mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM CSF. J. Clin. Invest. 117, 1902-1913 (2007).
218. Rini, B. I. et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758- 767 (2011).
219. Maker, A. V. et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
220. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
221. Stewart, R. et al. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J. Immunother. Cancer 2, 29 (2014).
222. Gomez-Roca, C. A. et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. J. Clin. Oncol. 33 (Suppl.; abstr.), 3005 (2015).
223. Simpson, T. R. et al. Fc dependent depletion of tumor-infiltrating regulatory T cells co defines the efficacy of anti-CTLA 4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
224. Selby, M. J. et al. Anti-CTLA 4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32-42 (2013).
225. Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28 (Suppl. 3), 39-48 (2014).
226. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD 1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B cell lymphoma. Blood 116, 3268-3277 (2010).
227. Ansell, S. M. et al. PD 1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
228. Taube, J. M. et al. Association of PD 1, PD 1 ligands, and other features of the tumor immune microenvironment with response to anti PD 1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014).
229. Paz-Ares, L. et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33 Suppl., LBA109 (2015).
230. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1504627 (2015).
231. Schellens, J. et al. CEA-targeted engineered IL2: clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. J. Clin. Oncol. 33 Suppl., 3016 (2015).
232. Sznol, M. & Chen, L. Antagonist antibodies to PD 1 and B7 H1 (PD L1) in the treatment of advanced human cancer-response. Clin. Cancer Res. 19, 5542 (2013).
233. Grosso, J. et al. Programmed death-ligand 1 (PD L1) expression in various tumor types. J. Immunother. Cancer 1 (Suppl 1), P53 (2013).
234. Brown, J. A. et al. Blockade of programmed death 1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257-1266 (2003).
235. Dong, H. et al. Tumor-associated B7 H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
236. Ohigashi, Y. et al. Clinical significance of programmed death 1 ligand 1 and programmed death 1 ligand 2 expression in human esophageal cancer. Clin. Cancer Res. 11, 2947-2953 (2005).
237. Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death 1 ligand/programmed death 1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151-2157 (2007).
238. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104, 3360-3365 (2007).
239. Gao, Q. et al. Overexpression of PD L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15, 971-979 (2009).
240. Latchman, Y. et al. PD L2 is a second ligand for PD 1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
241. Shi, M. et al. Expression of programmed cell death 1 ligand 2 (PD L2) is a distinguishing feature of primary mediastinal (thymic) large B cell lymphoma and associated with PDCD1LG2 copy gain. Am. J. Surg. Pathol. 38, 1715-1723 (2014).
242. Sun, Y. et al. B7 H3 and B7 H4 expression in non-small-cell lung cancer. Lung Cancer 53, 143-151 (2006).
243. Wu, C. P. et al. Relationship between co stimulatory molecule B7 H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 12, 457-459 (2006).
244. Crispen, P. L. et al. Tumor cell and tumor vasculature expression of B7 H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14, 5150-5157 (2008).
245. Loos, M. et al. Expression of the costimulatory molecule B7 H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9, 463 (2009).
246. Sun, J. et al. Clinical significance and regulation of the costimulatory molecule B7 H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 59, 1163- 1171 (2010).
247. Zang, X. et al. Tumor associated endothelial expression of B7 H3 predicts survival in ovarian carcinomas. Mod. Pathol. 23, 1104-1112 (2010).
248. Roth, T. J. et al. B7 H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900 (2007).
249. Boorjian, S. A. et al. T cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin. Cancer Res. 14, 4800-4808 (2008).
250. Tringler, B. et al. B7 H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11, 1842-1848 (2005).
251. Krambeck, A. E. et al. B7 H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103, 10391-10396 (2006).
252. Kryczek, I. et al. B7 H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881 (2006).
253. Simon, I. et al. B7 H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66, 1570-1575 (2006).
254. Tringler, B. et al. B7 H4 overexpression in ovarian tumors. Gynecol. Oncol. 100, 44-52 (2006).
255. Chen, L. J. et al. B7 H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60, 1047-1055 (2011).
256. Arigami, T. et al. Clinical significance of the B7 H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J. Surg. 35, 2051-2057 (2011).
257. Jiang, J. et al. Tumor expression of B7 H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59, 1707-1714 (2010).
258. Wang, Y. et al. α 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell. Melanoma Res. 23, 575-578 (2010).
259. Awadallah, N. S. et al. Detection of B7 H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36, 200-206 (2008).
260. Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. & Seliger, B. B7 H4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17, 3100-3111 (2011).
261. Schulkens, I. A. et al. Galectin expression profiling identifies galectin 1 and galectin 9d5 as prognostic factors in stage I/II non-small cell lung cancer. PLoS ONE 9, e107988 (2014).
262. Lahm, H. et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127, 375-386 (2001).
263. Lotan, R. et al. Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr. Res. 213, 47-57 (1991).
264. Miyazaki, J. et al. Increased expression of galectin 3 in primary gastric cancer and the metastatic lymph nodes. Oncol. Rep. 9, 1307-1312 (2002).
265. Pallesen, G. & Hamilton-Dutoit, S. J. Ki 1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am. J. Pathol. 133, 446-450 (1988).
266. Jilaveanu, L. B. et al. CD70 expression patterns in renal cell carcinoma. Hum. Pathol. 43, 1394-1399 (2012).
267. Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110, 2537-2544 (2007).
268. Schreiner, B. et al. Expression of the B7 related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 44, 296-301 (2003).
269. Martin-Orozco, N. et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T regulatory cells. Cancer Res. 70, 9581-9590 (2010).
270. Sloan, K. E. et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4, 73 (2004)